#AHA22
Virtual Experience Access
Sessions Posters
Late-Breaking Science
Daily Coverage
Industry Highlights
Featured Exhibitors
Program
Previews
AHA22
Uncovering novel approaches in heart failure science
AHA22
Trial results report on benefits of radial artery for CABG, use of prophylactic methylprednisolone and ECMO for patients in cardiogenic shock
AHA22
Trials’ results compare loop and thiazide diuretics and highlight ineffectiveness of novel fibrate therapy for reducing CV risk
Home
Late-Breaking Science announced
AHA21
Plan your schedule now for Late-Breaking Science
Watch now
AHA22
Early ablation bests medication in treatment naïve AFib patients
AHA22
First-in-class aminopeptidase-A inhibitor fails to reduce treatment-resistant hypertension
Sponsored
Data-driven precision medicine
Finding and helping patients with undiagnosed or undertreated cardiovascular diseases
AHA22
Trial results shed light on tool for assessing VTE risk, routine anticoagulation for non-hospitalized COVID patients, and clinical outcomes of open vs. endovascular surgery for advanced PAD
AHA22
Trials’ results highlight supplement ineffectiveness and potential for novel therapies to lower lipoprotein(a), reduce CKD progression
AHA22
Bivalirudin superior to unfractionated heparin in primary PCI following STEMI
Late-Breaking Science
Overcoming health disparities, health care advocates and mindfulness can better manage BP and CVD
AHA22
Join the Wellness Challenge at #AHA22
Download the Wellness App and use your fitness devices to compete with other attendees.
Home
Join us for Scientific Sessions 2022 in Chicago or online
Welcome back to the full experience of the world’s foremost celebration of cardiovascular and brain health science!
AHA21
Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption
AHA21
Update on local and global hypertension science
Late-breaking science uncovers findings about hypertension.
AHA21
Late-Breaking Science: New information in cardiac disease
AHA21
The latest science in heart failure
AHA21
Trials’ results highlight the potential for fish oil to fight COVID-19 and MK-0616 to lower cholesterol
AHA21
New drugs, indications in cardiovascular disease
AHA21
Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption
AHA21
Monday's Late-Breaking Science presentations
AHA21
#AHA21 highlights for Day 1
AHA21
Valves, veins and new viewpoints in cardiothoracic surgery
AHA21
Sunday's Late-Breaking Science presentations
AHA21
Valves, veins and new viewpoints in cardiothoracic surgery
AHA21
Sunday's Late-Breaking Science presentations